Sequence and Time-of-day Infusion of immunoCHemotherapy Affect Response in Oesophageal Cancer in the NeOadjuvant Setting

It is reported that compared to chemotherapy alone, immunochemotherapy has significantly improved the overall survival of patients with advanced metastatic ESCC. However, there are still more than 30% of patients who cannot benefit from this treatment modality. In addition to these factors, the time-of-day infusion and administration sequence of immunochemotherapy have been reported to be associated with tumor responses and overall survival. In this study, The investigators aimed to explore the roles of infusion time and administration sequence of immunochemotherapy in predicting tumor responses and overall survival in patients with advanced ESCC.

Inclusion Criteria:Pathologically diagnosed as esophageal squamous cell carcinomaKPS≥80Adequate organ functionNo distant metastasisThe diseases could be resected or potentially resectable after immunochemotherapy assessed by a thoracic oncologistExclusion Criteria:incomplete medical record which affects statistical analysishave participated in previous interventional clinical trialsother situations evaluated by investigators not meet the enrollment